The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.
Ping-Hung KoMeng Hsuan KuoI-Ting KaoChen-Yi WuChih-Wei TsengShih-Chieh ShaoPublished in: Viruses (2024)
cannot be ignored but may be avoided. Clinicians should consider implementing appropriate antiviral prophylaxis and monitoring policies for RA patients to avoid unnecessary hepatic side effects from tocilizumab treatment.
Keyphrases
- ankylosing spondylitis
- rheumatoid arthritis
- disease activity
- hepatitis b virus
- rheumatoid arthritis patients
- end stage renal disease
- interstitial lung disease
- juvenile idiopathic arthritis
- ejection fraction
- public health
- systemic lupus erythematosus
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- patient reported outcomes
- combination therapy